Screener
Kodiak Sciences Inc KOD Q3 2026 earnings
Reported November 12, 2026 · After market close
EPS-$1.05Beat by $0.01
EPS estimate-$1.06
“The DAYBREAK results reinforce Zenkuda's potential to become a first-line therapy in wet AMD, combining rapid disease control with a 24-week dosing interval for the majority of patients under strict treat-to-dry and maintain dry criteria reflective of real-world clinical practice. Tabirafusp-ted has delivered a positive Phase 3 readout in wet AMD and is actively enrolling in our Phase 3 ALTO study in diabetic macular edema. And KSI-101 is rapidly approaching its first pivotal readout in macular edema secondary to inflammation, a patient population with severe disease and no approved intravitreal biologic therapy. The breadth of this portfolio creates multiple opportunities to bring new medicines to patients across major retinal diseases.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Kodiak Sciences Inc report Q3 2026 earnings?
- Kodiak Sciences Inc (KOD) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Kodiak Sciences Inc's Q3 2026 revenue and EPS?
- Kodiak Sciences Inc reported eps of $-1.05 for Q3 2026.
- Did Kodiak Sciences Inc beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-1.06 by $0.01.
- How did Kodiak Sciences Inc's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 9.5% from $-1.16.
- Where can I find Kodiak Sciences Inc's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-458248) and the 10-Q periodic report (0001193125-26-458399) directly on SEC EDGAR. The filing index links above go to sec.gov.
